Back To Search Instructions
Protocols
9 protocol(s) meet the specified criteria
Age Group: A
Keyword: Neuroendocrine
Protocol No.TitleStatus
164512Multi-Center Chart Review Study in the US to Examine Treatment Patterns and Associated Outcomes among Patients with Advanced Neuroendocrine Tumors (NET) of Gastrointestinal (GI) OriginOpen
164513Multi-Center Chart Review Study in the US to Examine Treatment Patterns and Associated Outcomes among Patients with Advanced Neuroendocrine Tumors (NET) of Lung OriginOpen
165511Targeting Adaptive Pathways in Abiraterone and Enzalutamide Refractory Intermediate Atypical CarcinomaOpen
169524A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine CarcinomasOpen
17459Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver (RETNET): A phase 2 randomized multicenter trial to compare hepatic progression-free survival following bland embolization, lipiodol chemoembolization, and drug-eluting bead chemoembolization of neuroendocrine liver metastasesOpen
17705A pilot study of pembrolizumab and liver-directed therapy for patients with well-differentiated neuroendocrine tumors and symptomatic and/or progressive liver metastases Open
18954A PHASE 1 STUDY OF FOR46 ADMINISTERED EVERY 21 DAYS IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)Open
19551A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti-Programmed Cell Death 1 (PD-1) Monoclonal Antibody Pembrolizumab (PEMBRO; Keytruda) in Patients with Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC)Open
ALLIANCE-A021602RANDOMIZED, DOUBLE-BLINDED PHASE III STUDY OF CABOZANTINIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS AFTER PROGRESSION ON EVEROLIMUS (CABINET)Open